Home»Licensing NIH owned patents and data, including KEI comments on proposed exclusive licenses

Licensing NIH owned patents and data, including KEI comments on proposed exclusive licenses

(More on government funded inventions here)

2015

2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents, April 14, 2015.
2015: NIH refuses to give information about principals in company seeking exclusive license to HCV patents, May 5, 2015.

2016

2016: KEI comments on NIH proposal for exclusive licenses for vitro diagnostics patents to AltraTech, February 23, 2016.
2016: KEI/MSF comments to NIH on licensing of patents on Attenuated Respiratory Syncytial Virus (RSV) Vaccines, March 9, 2016.
2016: Objection to exclusive license to AestasRx Inc, April 8, 2016.
2016: Midissia Therapeutics license of NIH owned breast and prostate cancer vaccine patents, April 8, 2016.
2016: Great Lakes Neuroscience and NIH exclusive license on MS/ALS patent, April 10, 2016.
2016: NIH license on patents on 5T4 Antibodies for cancer treatment, diagnostics, to Ovensa, located in Ontario, Canada, April 17, 2016.
2016: NIH licenses on Boron Neutron patents, to Beijing Lanyears Communication, April 19, 2016.
2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds, May 4, 2016.
2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology, May 4, 2016.
2016: KEI comments on NIH proposal for exclusive licenses to Dedalus Pharma, LLC, May 9, 2016.
2016: AAVMediated Aquaporin Gene Transfer To Treat Sjögren’s Syndrome, May 16, 2016.
2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc., June 2, 2016.
2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation, June 2, 2016.
2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation, June 3, 2016.
2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC, June 3, 2016.
2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc., June 8, 2016.
2016: NIH Waivers for U.S. Manufacturing Requirements for Federally-Funded Drugs, September 17, 2016.
2016: Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute, October 19, 2016.
2016: Kite Pharma Uses CRADAs to Conduct Important Clinical Research on New Cancer Treatments, October 19, 2016.
2016: KEI comments on NIH proposed Exclusive License to Kite Pharma for Cancer Treatment, October 20, 2016.
2016: Front page New York Times story explores Kite Pharma’s profitable relationship with NIH regarding expensive cancer drug, Dec 20, 2016.

2017

2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors Useful for Treating Cancer, May 31, 2017.
2017: AbPro license of patents for liver cancer, June 2, 2017.
2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines, June 5, 2017.
2017: NantBioScience – Commercial Application and Use of Fulvestrant in Combination Therapy for the Treatment of Cancers, July 22, 2017.
2017: VeriLuce license of patents for pancreatic cancer treatment, July 31, 2017.
2017: Salubris Biotherapeutics: Bispecific, Biparatopic Antibody-Drug Conjugate for Human Liver Cancers, August 8, 2017.
2017: KEI initial comments on NIH proposed grant of exclusive license on liver cancer treatment to Salubris, August 8, 2017.
2017: miRecule/NIH license on MicroRNA Therapeutics for Treating Squamous Cell Carcinomas, August 18, 2017.
2017: Nanobernetics proposed exclusive license for NIH patents on Apparatus for Microarray Binding Sensors, September 6, 2017.
2017: National Institutes of Health proposed exclusive license for kidney cancer patents to company without its own phone number, Dec 21, 2017.
2017: KEI and MSF release comments on the proposed license of Zika vaccine candidates to PaxVax, November 13, 2017.
2017: NIH non-response response to KEI and MSF comments on the proposed exclusive license of Zika vaccine patents to PaxVax, Nov 30, 2017.

2018

2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology, January 5, 2018.
2018: KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite. February 27, 2018.
2018: KEI sues NIH over license of CD30 CAR T patents to Gilead, April 19, 2018.
2018: KEI, HealthGap comments on NIH exclusive license to Precision IBD for patents on TLIA Antibodies, May 23, 2018.
2018: Comments on Morphiex Biotherapeutics license (and NIH Response), May 30, 2018.
2018: NIH files motion to dismiss in KEI/NIH/Gilead CAR T license lawsuit, June 8, 2018.
2018: Comments on a prospective exclusive license of NIH-owned inventions to Beoro Therapeutics, June 22, 2018.
2018: KEI Files Expedited FOIA Request Regarding NIH Prospective Exclusive License of CAR T Technology, June 29, 2018.
2018: KEI comments on prospective exclusive NIH license to streptococcus pneumonia patents, for the University of Liverpool, July 3, 2018.
2018: NIH asked to extend comments on proposed license to Atara Biotherapeutics for patents on CAR T, July 9, 2018.
2018: KEI comments: ERYTHRYx Therapeutics: Prospective Grant of an Exclusive License on Methods of Modulating Erythropoiesis, July 9, 2018.
2018: KEI comments on the prospective grant of an exclusive license: Mutant IDH1 inhibitors for treating cancer to Apexx Oncology (and NIH Response), July 10, 2018.
2018: KEI comments on the NIH license on Anti-Mesothelin CAR to Atara Biotherapeutics, July 13, 2018.
2018: KEI and UACT comments on the prospective grant of an exclusive license to Midissia Therapeutics, August 13, 2018.
2018: KEI and T1International comments on the prospective grant of an exclusive license to Inversago Pharma, Inc, August 20, 2018.
2018: KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI, August 28, 2018.
2018: NIH Prospective Grant of an Exclusive Patent License to ElevateBio for CAR T cancer treatment, November 4, 2018.
2018: Comments on NIH Prospective Exclusive License on Diabetes Treatments, November 20, 2018.
2018: Comments on NIH license to Bull Run Capital, Inc. for safer non-lethal antagonist, December 16, 2018.

2019

2019: Joint Comments on NIH Prospective License to Sixfold Biosciences on Nanoparticles Technology (and NIH Response), January 7, 2019.
2019: Joint Comments on NIH Prospective License to Medigen on RSV and Parainfluenza Vaccines (and NIH Response), January 7, 2019.
2019: KEI comments on NIH prospective license to Morphiex on CD47 for solid tumors (and NIH Response), February 20, 2019.
2019: Joint comments on NIH prospective license to Ziopharm Oncology on cell therapies for cancer (and NIH Response), February 22, 2019.
2019: KEI comments on NIH License to BioE Holdings Inc for polyomaviruses vaccines (and NIH Response), February 22, 2019.
2019: Joint NGO comments on Senti Bio License for Development and Commercialization of Next Generation Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like tyrosine kinase 3 (FLT3) Expressing Cancers, April 19, 2019.
2019: KEI and UACT comments on NIH license to GLG Pharma over a STAT3 Inhibitor “in all proliferative diseases” (and NIH Response), June 7, 2019.
2019: KEI and UACT comment on NIH license to Tailored Therapeutics for the development and commercialization of cell therapies for cancer (and NIH Response), July 2, 2019.
2019: KEI and UACT comment on NIH license to Molecular Targeting Technologies, Inc. over Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors (and NIH Response), July 2, 2019.
2019. Joint Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead (and NIH Response), July 29, 2019.
- KEI, UACT, UAEM, and SSW Appeal NIH Grant of Exclusive Licenses on CAR Cancer Therapy to Gilead/Kite, September 12, 2019.
2019: Joint Comments Regarding NIH Proposed Exclusive License to Intima Biosciences for Cancer Therapy (and NIH Response), September 13, 2019.
- KEI, UACT, Public Citizen, SSW, LWC Health Appeal NIH Grant of Exclusive License on Gene Therapy for Cancer to Intima Biosciences, October 26, 2019.
2019: Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response), September 19, 2019.
2019: KEI and UACT Comments to NIH on License in AAV Vectors to Generation Bio and Spark Therapeutics, October 11, 2019.
2019: KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology (and NIH response), October 18, 2019.
2019: KEI Comments to the NIH on Exclusive License to Opsis Therapeutics for Retinal Cell Therapies, October 18, 2019.
2019: KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment, November 12, 2019.

2020

2020: KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease. January 10, 2020.
2020: KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy (and NIH Response). February 3, 2020.
2020: KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech. April 17, 2020.
2020: KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma. April 17, 2020.
2020: KEI Comments on NIH Exclusive License to Kriya Therapeutics for Diabetes and Obesity Treatment. April 30, 2020.
2020: KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment (and NIH Response). June 8, 2020.
2020: Joint Comments on Two NIH Exclusive Licenses to CAR Therapy to Vor Biopharma and Senti Bio. June 15, 2020.
2020: Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy (and NIH Response). July 6, 2020.
2020: KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment. July 7, 2020.
2020: KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies. July 27, 2020.
2020: KEI and UACT Comments Regarding NIH Exclusive License to Cytovia for CAR Technology. August 14, 2020.
2020: KEI Comments Regarding NIH Exclusive License to PreciThera (and NIH Response). August 20, 2020.
2020: KEI and UACT Comments Regarding NIH Exclusive License to ONK Therapeutics (and NIH Response). August 28, 2020.
2020: KEI and UACT Comments to NIH on Proposed Exclusive License to Connectyx. September 11, 2020.
2020: KEI Comments on Proposed Exclusive License to Connectyx for Degenerative Retinal Disease Treatment. November 6, 2020.
2020: KEI Comments on NIH Proposed Exclusive License to St. Louis University. December 3, 2020.

2021

2021: KEI Comments on NIH Exclusive License to Morphiex for Cancer Treatment. January 12, 2021.
2021: KEI Comments to NIH on Exclusive and Co-Exclusive Licenses to Senti Bio. January 12, 2021.
2021: KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment. February 9, 2021.
2021: KEI Comments on NIH Exclusive License to Canadian Firm EpifiZa. February 9, 2021.
2021: KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy. March 5, 2021.
2021: KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy. March 12, 2021.
2021: KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment. March 30, 2021.
2021: KEI Comments Regarding NIH Exclusive License to Memorial Sloan Kettering Cancer Center. April 14, 2021.
2021: KEI Comments on NIH Exclusive License to Norwegian Firm Zelluna. April 14, 2021.
2021: KEI Comments on NIH Exclusive License to Australian firm SubRed. April 26, 2021.
2021: KEI Comments to the NIH Regarding Prospective Exclusive License to UK firm Mevox. June 2, 2021.
2021: KEI Comments Concerning NIH Exclusive License to Kantum Pharma. June 8, 2021.
2021: KEI Comments Regarding NIH Exclusive License to Lyell Immunopharma for Cell Therapy Cancer Treatment. June 8, 2021.
2021: KEI Comments on NIH Exclusive License to Panacea for Gene Therapy. July 9, 2021.
2021: KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy. July 9, 2021.
2021: KEI Comments to the NIH on Exclusive License of AAV Technology to Children’s Medical Research Institute in Australia. July 14, 2021.
2021: KEI Comments Regarding NIH Proposed Exclusive License to Yeda. July 27, 2021.
2021: KEI Comments to NIH Regarding Proposed Exclusive License to PTC Therapeutics for Gene Therapy. July 27, 2021.
2021: KEI Comments Regarding NIH Exclusive License to Progeria Research Foundation for Ultra-Rare Disease Treatment. July 27, 2021.
2021: KEI Comments Regarding NIH Prospective License to Blue Water Vaccines for West Nile Vaccine. September 27, 2021.
2021: KEI Comments on NIH Prospective Exclusive License to Gilead for HIV Treatment/Cure. October 12, 2021.
2021: KEI comments on NIH proposed exclusive license to Neogene Therapeutics CRISPR-Engineered T Cell Therapies for the Treatment of Cancer. November 10, 2021.

2022

2022: KEI Comment to the NIH Regarding Exclusive License of Anti-Viral Prevention and Treatment. January 12, 2022.
2022: KEI Comments to NIH on Exclusive License to TeraImmune for T-cell Therapy for Multiple Sclerosis. February 9, 2022.
2022: KEI Comments Regarding NIH Exclusive License to Syncopation for CAR T Therapy. March 16, 2022.
2022: KEI Comments Regarding NIH Prospective Exclusive License to Georgetown University for Pancreatic Cancer Diagnostic. April 28, 2022.

2023

2023: KEI Comments Regarding NIH Prospective Exclusive License to Yissum R&D. February 8, 2023.
2023: KEI Comments to the NIH on Prospective Exclusive License to BrickBio Treatment for Solid Tumors. March 20, 2023.
2023: KEI Comments to NIH Regarding Prospective Exclusive License to Oncala Bio for Cancer Treatment. April 12, 2023.
2023: KEI Comments to the NIH Regarding the Prospective Grant of an Exclusive License to Elgia Therapeutics. August 4, 2023.
2023: KEI Exchange with the NIH Regarding April 2023 EnZeta Prospective License Notice. April 21, 2023.
2023: KEI Comments on NIH License to EnZeta Immunotherapies for Solid Tumors. August 18, 2023.
- KEI Questions to the NIH Regarding Prospective License of T-cell Cancer Therapy to EnZeta Immunotherapies. August 11, 2023.
2023: Scarlet TCR: Comments on a NIH prospective exclusive patent license for treatment of HPV cancers. October 6, 2023.
2023: KEI Comments Regarding NIH Proposed License T Cell Cancer Therapy to Moonlight Bio. October 12, 2023.
2023: KEI and Public Citizen Joint Comments on NIH License to Leyden for Coronavirus Treatment. November 3, 2023.

2024

- 2024. KEI Comments to the NIH License on Gene Therapy to Marble Therapeutics. February 22, 2024.
- 2024. KEI Comments to the NIH on Exclusive License to UK Firm Poolbeg Pharma. April 8, 2024.
- 2024. KEI Comments on NIH License to McSAF for Antibody-Drug Conjugates for Cancer. May 28, 2024.
- 2024. KEI Comments on NIH Exclusive License to INTcRON. June 4, 2024.
- 2024. KEI Comments on NIH Exclusive License to Autala for Autoimmune Treatment. September 4, 2024.
- 2024. KEI Comments to NIH on Exclusive License to T-Cure Biosciences for Anti-KK-LC-1 T Cell Receptors Patents. October 28, 2024.
- 2024. KEI Comments on NIH Exclusive License to Columbia for Ebola Technology. December 6, 2024.
- 2024: KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment. December 17, 2024.
- 2024: KEI Comments to the NIH on Cancer Treatment License to Straightline Bio. December 26, 2024.

2025

- 2025. KEI Comments on NIH Exclusive License to Sangam Lifesciences for Drug Delivery Platform. May, 7, 2025.
- 2025. KEI Comments to NIH on Exclusive License to Neurala. June 2, 2025.
- 2025. KEI Comments on NIH Prospective License To Chan Zuckerberg Biohub. July 17, 2025.
- 2025. KEI Comments on NIH Exclusive License to Capstan for CAR T Autoimmune Treatment. July 18, 2025.
- 2025. KEI Comments to the NIH on Exclusive License to Lysin Therapeutics. September 24, 2025.
- 2025. KEI Comments on Exclusive License of Zika Strain to AARI. October 14, 2025.
- 2025. KEI Comments on Exclusive License to Stage One Immunotherapeutics. October 20, 2025.

2026

- 2026. KEI Comments on Exclusive License to Kyverna Therapeutics. March 2, 2026.
- 2026. KEI Comments on NIH Prospective License to Perpetual Biosciences. April 20, 2026.